Search

Your search keyword '"Wassilios G. Meissner"' showing total 58 results

Search Constraints

Start Over You searched for: Author "Wassilios G. Meissner" Remove constraint Author: "Wassilios G. Meissner" Language english Remove constraint Language: english
58 results on '"Wassilios G. Meissner"'

Search Results

1. Early‐phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease

2. α-Synuclein-carrying astrocytic extracellular vesicles in Parkinson pathogenesis and diagnosis

3. Age and Gender Differences in Cardiovascular Autonomic Failure in the Transgenic PLP-syn Mouse, a Model of Multiple System Atrophy

4. Addressing knowledge gaps in Parkinson’s disease: a report on the Movement Disorder Society’s Centre-to-Centre initiative to improve Parkinson’s disease services in Lao People’s Democratic Republic

5. Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease

6. The European Reference Network for Rare Neurological Diseases

7. Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study

8. Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study

9. Deep brain stimulation does not enhance neuroinflammation in multiple system atrophy

10. Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy

11. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative

12. Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies

13. Deep brain stimulation changes basal ganglia output nuclei firing pattern in the dystonic hamster

14. Multiple system atrophy: current and future approaches to management

15. Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease

16. Addressing knowledge gaps in Parkinson’s disease: a report on the Movement Disorder Society’s Centre-to-Centre initiative to improve Parkinson’s disease services in Lao People’s Democratic Republic

17. Management of rare movement disorders in Europe

18. Clinical Conditions 'Suggestive of Progressive Supranuclear Palsy'—Diagnostic Performance

19. Neurofilament light levels predict clinical progression and death in multiple system atrophy

20. The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations

21. Multiple system atrophy

22. A comparative study on vowel articulation in Parkinson's disease and multiple system atrophy

23. Alterations in electrochemical skin conductance as a marker of autonomic dysfunction in multiple system atrophy

24. Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial

25. Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment

26. Cerebrospinal Fluid Levels of Kininogen‐1 Indicate Early Cognitive Impairment in Parkinson's Disease

27. Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy

28. Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction

29. Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study

30. Optimizing Treatment in Undertreated Late-Stage Parkinsonism : A Pragmatic Randomized Trial

31. Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study

32. A genome-wide genetic pleiotropy approach identified shared loci between multiple system atrophy and inflammatory bowel disease

33. Multiple System Atrophy: Recent Developments and Future Perspectives

34. A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control

35. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment

36. Deep brain stimulation does not enhance neuroinflammation in multiple system atrophy

37. Auton Neurosci

38. Coherent spike-wave oscillations in the cortex and subthalamic nucleus of the freely moving rat

39. Targeting α-synuclein: Therapeutic options

40. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations

41. Relevance of corpus callosum splenium versus middle cerebellar peduncle hyperintensity for FXTAS diagnosis in clinical practice

42. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

43. Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia

44. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracelullar striatal dopamine

45. Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies

46. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ('n-of-1') exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients

47. The natural history of multiple system atrophy: a prospective European cohort study

48. Priorities in Parkinson's disease research

49. The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research

50. Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia

Catalog

Books, media, physical & digital resources